Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Immedica Pharma, a Swedish company specializing in rare diseases, has announced its acquisition of Marinus Pharmaceuticals in a deal valued at $151 million. The agreement, finalized through a cash tender offer, marks a significant expansion of Immedica’s presence in the US market. 6 January 2025
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to establish a completely new production facility in Odense, Denmark. 16 December 2024
Pharmaceutical
The pharmaceutical and life sciences industry is gearing up for what analysts at PwC predict will be a highly active year for mergers and acquisitions in 2025, following a mixed performance in 2024. 13 December 2024
Pharmaceutical
Canada-headquartered Bausch + Lomb Corporation, a leading global eye health company, on Thursday confirmed reports that it is exploring a potential sale, acting in response to a request from the Canadian Investment Regulatory Organization (CIRO). 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Pharmaceutical
GE Healthcare has announced plans to acquire from Sumitomo Chemical the half of Nihon Medi-Physics (NMP) that it doesn’t own. 5 December 2024
Pharmaceutical
Germany’s Evotec has said its chief operating officer Craig Johnstone will leave the business at the end of the year. 29 November 2024
Pharmaceutical
Munich, Germany headquartered contract development and manufacturing organization (CDMO) Adragos Pharma has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. 28 November 2024
Pharmaceutical
The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield Capital Partners (UK) regarding a potential acquisition of Grifols shares. 28 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Pharmaceutical
US drugmaker Forest Laboratories (NYSE: FRX) says that Howard Solomon, its chairman, chief executive and president, will challenge a potential action by the Office of the Inspector General, Department of Health and Human Services (HHS-OIG), to exclude him from participation in federal health care programs, of which he was notified this week. Mr. Solomon was notified yesterday of the potential action in a letter from HHS-OIG. 15 April 2011
Pharmaceutical
Specialty US drugmaker ADVENTRX Pharmaceuticals (NYSE Amex: ANX) says that it has now completed its previously-announced all stock acquisition of SynthRx (The Pharma Letter February 15), which now becomes a wholly-owned subsidiary. 14 April 2011
Pharmaceutical
Acquisitive US drugmaker Endo Pharmaceuticals (Nasdaq: ENDP) has entered into a definitive accord to acquire American Medical Systems (AMS; Nasdaq: AMMD), a provider of world-class devices and therapies for male and female pelvic health, for $30 per share, or $2.9 billion in cash, which includes the assumption and repayment of $312 million of AMS debt. AMS' shares leapt 32.1% to $29.50 on the news, while Endo edged 0.5% higher to $41.06. 12 April 2011
Pharmaceutical
Sweden's Medivir AB (OMX Nordic: MVIR), an emerging research-based specialty pharmaceutical company focused on infectious diseases, has made an offer to acquire all the shares of BioPhausia AB (OMX Nordic: BIOP) a profitable, Sweden-based Nordic specialty pharma company and all Listed Warrants issued by BioPhausia. 12 April 2011
Pharmaceutical
USA-based Novelos Therapeutics (OTCBB: NVLT.ob), a developer of novel drugs for the treatment and diagnosis of cancer, says it has completed its acquisition of Cellectar, a Wisconsin-based drug development company, in a stock-for-stock transaction. 12 April 2011
Pharmaceutical
In what looks to be the last hurdle for Swiss drug major Novartis (NOVN: VX) to take full control of eye care specialist Alcon (NYSE:ACL), the latter's independent shareholders have approved the merger. Under the terms of the merger, Alcon shareholders will receive 2.9228 Novartis shares or American Depositary Shares plus a cash payment of $8.20 for each Alcon share. Completion is subject to approval by the Novartis shareholders, which will vote today (April 80. Following completion of the merger, Alcon will terminate its listing on the New York Stock Exchange. 8 April 2011
Pharmaceutical
Swiss drug major Novartis(NOVN: VX) has signed an agreement to sell to Swedish drugmaker Meda AB (MEDA: SS) the global rights to manufacture, market and commercialize Elidel (pimecrolimus) cream 1%, a treatment for mild to moderate atopic dermatitis. This agreement reflects Novartis strategy to focus commercialization on new launch portfolio and core brands, the company said. 7 April 2011
Pharmaceutical
US drug giant Merck & Co (NYSE: MRK) has entered into a definitive agreement under which Merck will to acquire specialty pharmaceutical company Inspire Pharmaceuticals (Nasdaq: ISPH), which is focused on developing and commercializing ophthalmic products, in a cash deal valuing the latter at around $430 million. 6 April 2011
Pharmaceutical
US drugmaker Cephalon (Nasdaq: CEPH) last evening said that, after a thorough review, its board of directors has formally rejected Canadian group Valeant Pharmaceuticals International's (TSX: VRX) hostile bid for the company for $73 a share, or a total of some $5.7 billion, saying the offer price was too low and the action was 'opportunistic' (The Pharma Letter March 30). 6 April 2011
Pharmaceutical
Forest Laboratories, Inc. (NYSE: FRX) says that it has extended the expiration date of its tender offer for all outstanding shares of common stock of, and certain outstanding notes and warrants convertible into the common stock of, Clinical Data (Nasdaq: CLDA) to expire at 12:00 midnight, New York City time on Monday, April 11, 2011. 6 April 2011
Pharmaceutical
In line with recent guidance that it is viewing the sale of some non-core businesses, global drugs behemoth Pfizer (NYSE: PFE) has entered into an agreement whereby an affiliate of private investment firm Kohlberg Kravis Roberts (KKR) will acquire Pfizer's Capsugel business for $2.375 billion in cash (The Pharma Letter March 15). 5 April 2011
Pharmaceutical
In another recent move on an Australian medical company, Netherlands-based Qiagen (Nasdaq: QGEN) has reached an agreement to acquire Cellestis (CST: AU) for around A$341 million ($355 million) in cash, providing Qiagen with access to a novel "pre-molecular" technology that offers a new dimension in disease detection not currently possible with other diagnostic methods. 5 April 2011
Pharmaceutical
Having itself made two acquisition moves in the last two weeks, US drugmaker Cephalon (Nasdaq: CEPH) last night became the subject of a hostile takeover bid from Canada's largest drug firm, Valeant Pharmaceuticals International (TSX: VRX). 30 March 2011
Pharmaceutical
Sanofi-Aventis (Euronext: SAN) says that the registration statement relating to the Contingent Value Rights (CVRs) offered to Genzyme shareholders as part of the French drug major's revised agreement to acquire US biotech firm Genzyme (The Pharma Letters passim) has been declared effective by the US Securities and Exchange Commission. 30 March 2011
Pharmaceutical
AltheRx Pharmaceuticals, a privately-held US clinical development company set up just a year ago, says it has purchased all assets related to solabegron (GW-427353) from UK pharma giant GlaxoSmithKline (LSE: GSK), making it the first product for the US firm. 29 March 2011
Pharmaceutical
The US Federal Trade Commission has withdraw its appeal Laboratory Corporation of America's (NYSE: LH) 2010 $57.5 million acquisition of Westcliff Medical Laboratories (The Pharma Letter December 3, 2010). Although LabCorp consummated the acquisition in June 2010, the FTC was seeking the federal court injunction to prevent LabCorp from integrating the companies pending the outcome of administrative litigation. The FTC also has withdrawn the matter from administrative adjudication - a step that stops the trial proceedings, but does not conclude the case. 28 March 2011
Pharmaceutical
US consumer products conglomerate Procter & Gamble (NYSE: PG) and Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) have signed an agreement to create a partnership in consumer health care by bringing together both companies' existing over-the-counter (OTC) medicines and complementary capabilities to accelerate growth. 25 March 2011
Pharmaceutical
USA-based specialty pharma company CPEX Pharmaceuticals (Nasdaq: CPEX) says that, , based on the vote count certified by the independent inspector of election its shareholders have approved the company's proposed $76.6 million merger agreement with FCB I Holdings, which is majority owned by Footstar Corp, at the special meeting of stockholders held yesterday (The Pharma Letter January 5). 25 March 2011
Pharmaceutical
Merck & Co and Sanofi-Aventis drop plans to merge animal health operations; latter prices bond issue
In something of an embarrassing climb-down on plans to create the world's biggest animal health company, pharma majors Merck & Co (NYSE: MRK) and Sanofi-Aventis (Euronext: SAN) have mutually agreed to scrap their accord to form a new joint venture with combined sales of some $5.5 billion. The aim had been to combine Merial, the animal health business of Sanofi with Intervet/Schering-Plough, Merck's animal health unit. As a result, each party will keep its current, separate animal health assets and businesses. 23 March 2011
Pharmaceutical
Darmstadt -based Merck KGaA (MRK: DE) has entered into a definitive agreement to acquire the microbiology business of fellow German company Biotest AG. Financial terms of the accord were not disclosed. It is planned to integrate Biotest's microbiology activities into Merck Millipore's Lab Solutions business unit. 23 March 2011
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze